The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C) (CIBS)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01722318 |
|
Recruitment Status :
Completed
First Posted : November 6, 2012
Results First Posted : September 17, 2018
Last Update Posted : May 28, 2019
|
Sponsor:
Bausch Health Americas, Inc.
Information provided by (Responsible Party):
Bausch Health Americas, Inc.
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
This is a randomized, 12-week, double-blind, placebo-controlled, dose-ranging study in patients with IBS-C.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Irritable Bowel Syndrome Characterized by Constipation | Drug: Plecanatide Drug: Placebo | Phase 2 |
This is a randomized, 12-week, double-blind, placebo-controlled, dose-ranging study in patients with IBS-C. Patients will undergo a Screening Period to determine eligibility. After completing a Screening Visit patients will undergo a 2-week Pre-Treatment assessment using the Interactive Voice Response System (IVRS) during which they will complete daily assessments of bowel movements (BMs), stool consistency (Bristol Stool Form Scale- BSFS), abdominal pain or abdominal discomfort and other symptoms associated with IBS-C. Data from the two-week IVRS Pre-treatment assessment are used to define the patient's baseline from which change will be determined. Patients who meet all entry criteria will be randomized to one of five treatment groups ( 0.3mg,1.0mg,3.0mg,9mg,or Placebo) on Day 1 of the Treatment Period. Patients will take an oral dose of study drug daily (QD) for 12 weeks and continue the daily IVRS diaries (BMs, abdominal pain, other symptoms). On Weeks 2, 4, 8, and 12, patients will return to the clinic to undergo safety and efficacy assessments. For 2 weeks after completing dosing, (i.e., Post-Treatment Period), patients will continue to complete daily IVRS diaries. Patients will then return to the clinical site for a final follow-up visit (End of Study Visit). The planned duration of participation in this study will be approximately 112 days from signing of informed consent through post-treatment or 145 days if 30 day washout of a prohibited concomitant medication or stabilization of a medical condition is required before Pre-Treatment (up to 148 days, with all windows considered).
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 428 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Triple (Participant, Care Provider, Investigator) |
| Primary Purpose: | Treatment |
| Official Title: | A Randomized, 12-Week, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of Plecanatide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C) |
| Study Start Date : | November 2012 |
| Actual Primary Completion Date : | April 2014 |
| Actual Study Completion Date : | October 2014 |
Resource links provided by the National Library of Medicine
MedlinePlus related topics:
Constipation
Drug Information available for:
Plecanatide
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Plecanatide 0.3mg
Plecanatide 0.3mg, one tablet by mouth daily for 12 weeks
|
Drug: Plecanatide
Other Name: Trulance |
|
Active Comparator: Plecanatide 1.0mg
Plecanatide 1.0mg one tablet by mouth daily for 12 weeks
|
Drug: Plecanatide
Other Name: Trulance |
|
Active Comparator: Plecanatide 3.0mg
Plecanatide 3.0mg, one tablet by mouth daily for 12 weeks
|
Drug: Plecanatide
Other Name: Trulance |
|
Active Comparator: Plecanatide 9.0mg
Plecanatide 9.0mg, one tablet by mouth daily for 12 weeks
|
Drug: Plecanatide
Other Name: Trulance |
|
Placebo Comparator: Placebo
Placebo, one tablet by mouth daily for 12 weeks
|
Drug: Placebo |
Primary Outcome Measures :
- Change From Baseline in Weekly CSBMs Frequency Over the 12-Week Treatment Period (mITT Population) [ Time Frame: 12 weeks Treatment Period ]The primary efficacy endpoint was the change from baseline in the weekly CSBM frequency (CSBMs per week minus CSBMs per week at baseline) over a 12-week Treatment Period. A Complete Spontaneous Bowel Movement (CSBM) is a Bowel Movement (BM) that occurs in the absence of laxative use within 24 hours of the BM and the patient reports a feeling of complete evacuation.
Secondary Outcome Measures :
- Change From Baseline in Abdominal Pain Intensity Scores Over 12-Week Treatment Period (mITT Population) [ Time Frame: 12-Week Treatment Period ]Abdominal Pain was assessed in the patient's daily response on a scale of 0 to 10 where 0 is did not experience the symptom at all and 10 is experienced the worst.
- Change From Baseline in Stool Consistency (BSFS) Over 12-Week Treatment Period (mITT Population) [ Time Frame: 12-Week Treatment Period ]
The stool consistency of each bowel movement (BM) was assessed by patients using the 7-point Bristol Stool Form Scale [BSFS] from 1 to 7.
- = separate hard lumps like nuts (difficult to pass)
- = sausage shaped but lumpy
- = like a sausage but with cracks on its surface
- = like a sausage or snake, smooth and soft
- = soft blobs with clear-cut edges (passed easily)
- = fluffy pieces with ragged edges, a mushy stool
- = watery, no solid pieces (entirely liquid)
- Change From Baseline in Straining Scores Over 12-Week Treatment Period (mITT Population) [ Time Frame: 12-Week Treatment Period ]The severity of straining (Straining Score) was rated by the patients using a 11-point scale (0-10) where 0 = none and 10 = very severe
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Male or female aged 18-75, inclusive
- Body Mass Index = 18-35 kg/m2, inclusive
- Meets modified Rome III criteria for irritable bowel syndrome with constipation which includes abdominal pain or discomfort for at least 3 days/month in the last 3 months with symptom onset for at least 6 months.
- Less than 3 CSBMs and less than 6 SBMs per week during the last 3 months.
- Hard or lumpy stools ≥ 25 % of defecations
- Patient has average abdominal pain intensity scores ≥ 3 (scale 0-10)for the combined 2 week pre-treatment period
- Patient is willing to discontinue use of supplemental fiber, laxatives, prescription and nonprescription medications, herbal or dietary supplements intended to treat constipation during the screening, pre-treatment, treatment and 2-week post-treatment periods
- Willing to maintain a stable diet during the study.
- Patients with hemorrhoids and/or diverticulosis (NOT diverticulitis) CAN be entered into the study.
Exclusion Criteria:
- Loose stool (mushy) or watery stool in the absence of any laxative or prohibited medicine for > 25% of BMs during the 3 months prior to screening visit OR during the 14 day pre-treatment period
- Patient has diarrhea-predominant or mixed ( diarrhea and constipation cycling or diarrhea and normal cycling) IBS.
- Active peptic ulcer disease not adequately treated or not stable
- History of cathartic colon, laxative, enema abuse, or ischemic colitis.
- Fecal impaction within 3 months of screening
- Patient has had /has any: structural abnormality of the GI tract or gastric bypass surgery, pelvic floor dysfunction, pseudo-obstruction, active infectious gastritis, diverticulitis, anal fissures or any disease or condition that can affect GI motility or defecation or can be associated with abdominal pain
- Unexplained and clinically significant "alarm symptoms" including lower GI bleeding, iron-deficiency anemia, weight loss or systemic signs of infection or colitis.
- Major surgery within 60 days of screening.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01722318
Locations
Show 99 study locations
Sponsors and Collaborators
Bausch Health Americas, Inc.
Investigators
| Principal Investigator: | Philip B Miner, MD | Oklahoma Foundation for Digestive Research |
| Responsible Party: | Bausch Health Americas, Inc. |
| ClinicalTrials.gov Identifier: | NCT01722318 |
| Other Study ID Numbers: |
SP304-20212 |
| First Posted: | November 6, 2012 Key Record Dates |
| Results First Posted: | September 17, 2018 |
| Last Update Posted: | May 28, 2019 |
| Last Verified: | May 2019 |
Additional relevant MeSH terms:
|
Irritable Bowel Syndrome Syndrome Constipation Disease Pathologic Processes Signs and Symptoms, Digestive Colonic Diseases, Functional Colonic Diseases |
Intestinal Diseases Gastrointestinal Diseases Digestive System Diseases Plecanatide Guanylyl Cyclase C Agonists Enzyme Activators Molecular Mechanisms of Pharmacological Action Gastrointestinal Agents |